Background Acute kidney injury (AKI) staging has been developed in the adult and pediatric populations, but these do not yet exist for the neonatal population. Metabolomics was utilized to uncover biomarkers of normal and AKI-associated renal function in preterm infants. The study comprised 20 preterm infants with an AKI diagnosis who were matched by gestational age and gender to 20 infants without an AKI diagnosis. Methods Urine samples from pre-term newborn infants collected on day 2 of life were analyzed using broad-spectrum nuclear magnetic resonance (NMR) metabolomics. Multivariate analysis methods were used to identify metabolite profiles that differentiated AKI and no AKI, and to identify a metabolomics profile correlating with gestational age in infants with and without AKI. Results There was a clear distinction between the AKI and no-AKI profiles. Two previously identified biomarkers of AKI, hippurate and homovanillate, differentiated AKI from no-AKI profiles. Pathway analysis revealed similarities to cholinergic neurons, prenatal nicotine exposure on pancreatic β cells, and amitraz-induced inhibition of insulin secretion. Additionally, a pH difference was noted. Both pH and the metabolites were found to be associated with AKI; however, only the metabotype was a significant predictor of AKI. Pathways for the no-AKI group that correlated uniquely with gestational age included aminoacyl-t-RNA biosynthesis, whereas pathways in the AKI group yielded potential metabolite changes in pyruvate metabolism. Conclusions Metabolomics was able to differentiate the urinary profiles of neonates with and without an AKI diagnosis and metabolic developmental profiles correlated with gestational age. Further studies in larger cohorts are needed to validate these results.
Introduction
Premature infants are born with a paucity of nephrons, which are underdeveloped, and at different levels of maturity at birth. Full nephrogenesis continues until 36 weeks' gestation, and unfortunately, the extra-uterine environment is often not hospitable for proper nephrogenesis. Premature infants are at risk for short-and long-term kidney disease. Acute kidney injury (AKI) among premature neonates is multifactorial and often due to infection, perinatal distress, and exposure to nephrotoxic medications [1] . The incidence of AKI in premature infants is estimated to be between 12.5 and 39.8 % during the first weeks of life [2] [3] [4] , and those with AKI have significantly worse outcomes in terms of mortality [5] . Most of these studies have used a rise in serum creatinine (SCr) from baseline level by 0.3 mg/dl to diagnose AKI [2] . Metabolomics may provide an insight into the diagnosis of neonatal AKI, and the changing development of the newborn.
Urinary metabolomic studies have been used to uncover markers of disease [6] [7] [8] , and are particularly promising and relevant in the neonatal community, as they utilize a bio-fluid that is readily available under most circumstances. Urine metabolomics have been used to document changes across developmental age; yet, there is so much more to uncover. Metabolomics applications could be employed to evaluate the differences across neonatal developmental stages, the impact of AKI on different metabolomics pathways, the environmental exposures that lead to poor development and kidney injury, the nutritional demands of growing premature infants, and to uncover urine biomarkers of many diseases [9] . All of these could improve the outcomes and understanding of the target pathways for certain diseases [8] . In addition, these urinary metabolites could provide clinicians with real-time information for earlier diagnosis and intervention [8] .
To date, no studies have fully described the developmental urinary metabolomic profiles of preterm neonates in the context of AKI. In addition to the disease state, samples derived at baseline and from well-matched controls are important in understanding normal developmental stages, particularly in premature infants in whom renal development may be occurring ex utero.
We performed a prospective nested case-control study to improve our understanding of the metabolomics in premature infants. We evaluated the differences in the urine metabolome between infants with AKI and those without AKI (matched by gestational age and gender). Additionally, we evaluated the differences in the urine profiles across different gestational age categories in neonates with and without AKI.
Materials and methods

Human subjects study population
This prospective nested case-control study was performed on a cohort of very low birth weight (VLBW) infants admitted to the regional NICU between February 2012 and June 2013. Infants who met the inclusion criteria (birth weight [BW] ≤ 1,200 g and/or ≤31 weeks gestational age) and exclusion criteria (known congenital kidney disease or if they did not survive beyond the first 48 hours of life) were approached to participate in this study. Prospective data were collected on 122 infants. For this metabolomics investigation 20 infants who met the diagnostic criteria for AKI were selected as cases and were matched by gestational age (± 1 week) and gender. Twenty similar infants without AKI were chosen as controls, as shown in Table 1 . Cases and controls were selected to ensure that we had an equal representation of gestational categories (<27 weeks, 27-28 weeks, and > 28 weeks' gestation). There was no significant difference between AKI and no-AKI patients with regard to gestational age (p = 0.84), birth weight (p = 0.84), and gender (p = 0.52).
Acute kidney injury was diagnosed in the context of this study if an infant had a rise in serum creatinine (SCr) of 0.3 mg/dl from baseline, as defined by the Kidney Disease Improving Global Outcomes Definition (KDIGO), during the first week of life. SCr was prospectively collected on days 1, 2, 3, and 4 of life in addition to any clinically measured SCr values.
NMR metabolomics
Urine was collected on day 2 of life using cuddle buns™ (Small Beginnings, Hesperia, CA, USA) diapers placed at the perineum. Urine was squeezed from the fibers of the diaper with a syringe onto a laboratory tube, which was then centrifuged at 15,000 rpm for 10 min to remove any particulates. Samples were then stored at −80°C within 2-6 h of collection until measurements by metabolomics analysis, similar to other metabolomics studies [10] [11] [12] [13] . No preservatives were added to the urine samples, as previous studies have shown that urinary metabolites are stable for at least 4 weeks [14] and the use of preservatives when storing samples at −80°C has little to no impact on the resulting metabolomics profiles [15] .
All 40 urine samples were analyzed using nuclear magnetic resonance (NMR) spectroscopy to analyze the metabolites that differentiated the urine from infants with and without AKI diagnosis. Sample preparation, data acquisition, data analysis, and pathway analysis followed procedures previously described [16] [17] [18] [19] [20] [21] . Briefly, each of the 40 urine samples (200 μL) were prepared individually by the addition of 25 μL D 2 0 and 25 μL Chenomx Internal Standard (Chenomx ISTD, Edmonton, AB, Canada).
Phenotypic pools for AKI and no AKI were generated with 60 μL of each urine sample pooled, mixed, and divided into three aliquots. Additionally, 400 μL from both phenotypic pools were mixed to form a total pooled sample and divided into three aliquots. These pooled samples were prepared in an identical manner to the individual study samples. Metabolomics data were acquired for each of the individual study samples and for the pooled samples. 1 H NMR spectra of urine samples were acquired on a Bruker Avance III 950 MHz NMR spectrometer housed at the David H. Murdock Research Institute in Kannapolis, NC, USA. Spectra were collected using the 1D NOESY presaturation pulse sequence (noesypr1d) and were pre-processed using an ACD 1D NMR Processor 12.0 (ACD Labs, Toronto, ON, Canada). NMR bins (0.50-9.00 ppm) were made after excluding water (4.68-4.88 ppm), urea (5.60-6.00 ppm), and imidazole (7.20-7.28 ppm) using an intelligent binning width of 0.04 ppm and a 50 % looseness factor. Integrals of each of the bins were normalized to the total integral of each spectrum.
Multivariate and statistical analysis
Normalized binned NMR data were Pareto scaled and centered before multivariate analysis. The metabolomic profiles of the AKI and no-AKI patients were analyzed to determine the urinary markers of AKI for all of the gestational ages. Then, the AKI and no-AKI profiles were compared separately to understand the differences in development in the presence and absence of AKI. Multivariate data analysis methods (e.g., principal component analysis [PCA] , orthogonal partial least squares [OPLS] , and orthogonal partial least squares discriminant analysis [OPLS-DA]) were used to reduce the dimensionality and to enable the visualization of the separation of the study groups (SIMCA 14; Umetrics, Umeå, Sweden) [22, 23] . The PCA scores plots were inspected to ensure that the phenotypic pooled samples were tightly clustered in the center of phenotypic groups and that the pools of all individual study samples clustered in the center of all samples, a quality control method that is widely used in metabolomic studies [24] . Loadings plots and a variable influence on projection (VIP) plots were inspected, and bins that had a VIP ≥ 1.0 with a jack-knife confidence interval that did not include 0 were determined to be important for differentiating the study groups. The VIP statistic summarizes the importance of the bin in differentiating the phenotypic groups [23] . All models used a 7-fold cross-validation to assess the predictive variation of the model (Q 2 ). Chenomx NMR Suite 7.7 Professional software (Edmonton, Alberta, Canada), which has a concentration library of approximately 350 compounds, and the HMDB reference library were used to match the signals in the identified bins to metabolites [25] [26] [27] . Moreover, hippurate and homovanillate were fit for relative concentration determination using Chenomx. The pH of each spectrum was calculated based on the imidazole chemical shift compared with the residual water resonance [28] .
Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Statistical tests for continuous variables that were non-normally distributed were conducted using the Mann-Whitney U test; otherwise, a two-sided t test with the Satterthwaite correction for unequal variances was used. The Chi-squared test was used to test for differences in categorical variables and Fisher's exact test was used when cell counts were small. Logistic regression was used to predict the diagnosis of AKI using calculated pH (categorized at the mean pH level of 7.4) alone, the metabotype alone, and both pH and metabotype. The predictive component scores from the multivariate AKI OPLS-DA model were used to define the metabotype. For this exploratory study, p values < 0.05 were considered to be statistically significant and were not adjusted for multiple testing [29, 30] .
Pathway analysis
Using the results of the supervised multivariate analyses, library-matched metabolites were analyzed for pathway enrichment using the knowledge-based canonical pathways and endogenous metabolic pathways in the MetaCore, by
Thomson Reuters (Philadelphia, PA, USA). Ranking of relevant pathways was based on hypergeometric p values.
Results
Metabolites that differentiate AKI from no-AKI profiles Unsupervised (PCA, Fig. 1a ) and supervised (OPLS-DA, Fig. 1b ) multivariate analyses were used to determine the metabolites responsible for differentiating neonates diagnosed with AKI from those without an AKI diagnosis. While no clustering was observed, as defined by the phenotypic anchors in the PCA, a clear distinction was observed by OPLS-DA between the AKI and non-AKI profiles (1 predictive and (cum) = −0.189, 80 % correct for the cases and 90 % correct for the controls with a Fisher's probability = 8.3E-6). The receiver operating characteristic (ROC) curve is shown in Fig. 1c , and the area under the receiver operating characteristic (AUROC) curve was 0.93. Table 2 shows the library-matched bins that had a VIP ≥ 1 with a jack-knife confidence interval that did not include 0 and were determined to be important to separating the groups. One of the bins important to differentiating the AKI diagnosis groups contained hippurate and homovanillate (VIP = 4.7, p = 0.04, fold change = −2.1), which have been previously implicated in nephrotoxicity [31] [32] [33] . Both hippurate and homovanillate were fit for relative concentrations. The mean hippurate concentration was 82.3 μM (SD = 85.4) for AKI and 59.7 μM (SD = 28.5) for no-AKI (p = 0.27) profiles. The mean homovanillate concentration was 39.3 μM (SD = 48.9) for AKI and 38.7 μM (SD = 35.5) for no-AKI (p = 0.97) profiles. Pathway mapping suggests that the metabolic differences between groups could be related to cholinergic neurons, the prenatal nicotine exposure of pancreatic β cells, and amitraz-induced inhibition of insulin secretion, as shown in Fig. 1d . A shift in the imidazole resonances (pH indicator) in NMR spectra, as shown in Fig. 2a , was observed during the inspection of the QC pooled samples. This shift indicates that the samples potentially have different pH values; therefore, the pH of each of the individual urine samples was calculated [28] , and the pH was found to be statistically different ( = 0.007) between infants with an AKI diagnosis (mean = 7.5, SD = 0.3) and those without an AKI diagnosis (mean = 7.3, SD = 0.2). Given the key contribution that the kidneys provide in maintaining an acid-base balance and the existence of renal tubular acidosis of the newborn, this was a compelling finding [34] . The distribution of pH according to AKI diagnosis is shown in Fig. 2b .
To further explore the pH difference, logistic regression modeling was utilized to understand the predictive nature of the pH and metabolomics profiles. The results of the logistic regression modeling to predict the diagnosis of AKI showed that Table 2 Metabolites that differentiated acute kidney injury (AKI) from no-AKI urinary profiles. The positive fold change means that the peak intensity of AKI is higher than non-AKI. Two bins were not identified through the Chenomx library matching, because they were deemed significant and were high variable influence on projection (VIP); future studies will involve identifying these metabolites using 2D nuclear magnetic resonance (NMR) techniques high pH (> 7.4) is predictive of an AKI diagnosis when it is the only predictor included in the model. Similarly, the metabotype alone was also predictive of AKI. When both pH and the metabotype were included in the model, only the metabotype was a significant predictor of AKI. Figure 3 shows the comparisons of the ROC curves for the three models and Table 3 shows the 95 % confidence interval for each model's AUROC curve. The AUROC curve for the models, including the metabotype, are significantly higher (AUROC curve = 0.9) than the AUROC for the pH-only model (AUROC curve = 0.7, p < 0.001).
Metabolites associated with gestational age categories
The urinary profiles of the neonates were investigated by OPLS regression using gestational age (measured in days) to correlate the metabolomics data with gestational age for infants diagnosed with AKI and those without an AKI diagnosis. Figure 4a and b show the trajectory of the gestational ages according to AKI status in OPLS models, whereas Fig. 4c and d demonstrate the prediction of gestational age in patients without AKI through the metabolomics data. Tables 4 and 5 list the metabolites that were identified as being important to the prediction of gestational age with VIP, whereas Table 6 includes a comprehensive list of metabolites unique to the AKI and no-AKI profiles, and common metabolites for both groups that correlated with gestational age. The functional ontology was created for AKI-and no-AKI-correlated metabolites to understand gestational age. Aminoacyl-t-RNA biosynthesis in the mitochondria and cytoplasm were the top scoring probable pathways identified for the unique no-AKI metabolites (Fig. 5a ), whereas the unique AKI metabolites yielded potential changes in pyruvate metabolism (Fig. 5b) . The common metabolites for the gestational age prediction also show (Fig. 5c ) that the biochemical pathways important for describing the gestational ages of all the neonates is aminoacyl-tRNA biosynthesis
Discussion
To our knowledge, urinary metabolomic profiles of preterm neonates with AKI have not been examined previously. This Tables 4 and 5 metabolomics study sought to understand the differences between the urinary metabolomic profiles of neonates with and without AKI, controlling for gender and gestational age. Additionally, it was hypothesized that the urine metabolome differs across different gestational age categories in neonates with and without AKI and can correlate with gestational age. To understand the differences between infants with an AKI diagnosis and those without, metabolomics profiles were evaluated by unsupervised and supervised multivariate analysis. The infants with an AKI diagnosis could be differentiated from those without a diagnosis based on the supervised analysis (Fig. 1b) , and the metabolites important to differentiating between AKI and non-AKI were determined with librarymatching. The highest VIP bin contained hippurate and homovanillate, both of which have been previously implicated in nephrotoxicity [31] [32] [33] . Formerly, the homovanillate had been noted to be elevated in the AKI patients, whereas in this cohort, the homovanillate was lower. It appears that the directionality of the NMR bin is driven by the hippurate change. Hippurate has been noted to be decreased in nephrotoxicology studies [32] , and this corresponds with our findings. Plasma tyrosine metabolism has also been noted to be perturbed in previous AKI studies [35, 36] . Metabolites important to differentiating between infants with and without an AKI diagnosis demonstrated that the process implicated in AKI could be related to cholinergic neurons, prenatal nicotine exposure on pancreatic β cells, and amitraz-induced inhibition of insulin secretion, as shown in Fig. 1d . Interestingly, cholinergic receptors are found in intercalated cells (ICCs), which regulate aquaporins [37] . These ICCs also help regulate the pH throughout the kidneys, making a compelling connection between the pathway analysis and the pH differences observed in samples from infants with an AKI diagnosis compared with infants without AKI. Animal investigations have also implicated a possible common toxic pathway response for AKI and amitraz [38] . Although the toxic effects from the amitraz were reversed with alpha2-adrenergic antagonists, the patient suffered from AKI, demonstrated by the presence of severe, acute, multifocal, glomerular, and tubular necrosis. Prenatal nicotine exposure has been linked to oxidative stress in the kidneys [39] . Pathways associated with oxidative stress have also observed in cases such as contrast medium-induced AKI in diabetic patients [40] .
Several factors, including infection, perinatal distress, and exposure to nephrotoxic medications, lead to AKI susceptibility in the neonate [1] . Understanding the biomarkers associated with and the impact of AKI on neonatal kidney function is important for early detection and intervention. In this study, urinary metabolomic analysis was utilized to investigate the developing non-AKI and AKI kidneys with urinary profiles of neonatal infants between the gestational ages of 23-31 weeks. The OPLS regression model and NMR library-matching investigations found metabolites to be important in the correlation with changing gestational age. For infants without an AKI diagnosis, gestational age correlated with metabolites of aminoacyl-t-RNA biosynthesis, suggesting that this might be a process modulated during the observed gestational age range. This is a key pathway as it regulates amino acid synthesis, and the proximal tubules of the kidneys are responsible for hydrolyzing small proteins [41] . The degradation of β2 microglobulin, in particular, has correlated with gestational age, reflecting maturing proximal renal tubular function [42] . Gluconate was identified as one of the highest VIPs in this analysis. However, it is unclear if this was due to differences occurring in the neonates during gestational weeks [23] [24] [25] [26] [27] [28] [29] [30] [31] or if it is due to differences in trophic feeding strategies [43, 44] . For infants diagnosed with AKI, gestational age correlated with metabolites that suggest that pyruvate metabolism might be a process that is modulated during this gestational age range.
Pyruvate metabolism has previously been demonstrated to be Fig. 5 Curated pathways important to the correlation with gestational age that are unique to neonates a without an acute kidney injury (AKI) diagnosis, b with an AKI diagnosis, and c common to all neonates regardless of AKI diagnosis downregulated in a kidney cancer metabolomics and proteomics study, as were the pathways closely associated with gluconeogenesis [45] . The specific nature of pyruvate metabolism in the presence of renal injury is yet to be fully understood. Both propylene glycol and ethylene glycol were found to be predictors of gestational age in premature neonates with AKI. Many external factors have been proposed to contribute to malfunction of neonatal kidneys, including maternal diet, stress, hypertension, and drugs administered to the mother or to the newborn [46, 47] . Drug formulations, in particular, contain propylene glycol and poly-ethylene glycol, which are cosolvents and could be a factor in the kidney injury [48] [49] [50] or a possible environmental contaminant.
For all infants in our cohort, threonine was important to the correlation with gestational age. We also found that for infants without an AKI diagnosis, glycine was important to the correlation with gestational age. Both metabolites have been discussed previously in urinary metabolomics of neonates as markers of insufficient growth in utero [51, 52] . It has been suggested that because both of these amino acids are glucogenic, an increase in glycine might cause a reduction of amino acid oxidation or reduced glucogenesis as a means of conservation [53] . In addition, Atzori and colleagues found that amino acids differentiated preterm (23-32 weeks GA) from term infants (33-36 weeks GA), including both hippurate and proline [10] . Atzori and colleagues also found that tryptophan, phenylalanine, malate, tyrosine, x-hydroxybutyrate, and Nacetylglutamate were important in differentiating preterm from term infants, but were not found to predict gestational age in the no-AKI infants in this cohort. Furthermore, in a study of infants with intrauterine growth retardation (IUGA) compared with adequate (AGA) and large (LGA) for gestational age, the two metabolites that best differentiated between these urinary profiles were myo-inositol and creatinine, which the authors postulate might be related to a hypo-insulinemic condition from which the IUGA fetuses suffer. This correlates well with the finding described here and elsewhere that threonine and glycine are descriptors of insufficient in utero growth [13] .
The AKI-associated profiles in this gestational range cohort indicated that pyruvate metabolism was being modulated, so the important difference in the renal development of neonates with an AKI diagnosis compared with those without could very well be related to energy metabolism. It has been observed previously that the accumulation of calcium and magnesium during energy metabolism causes damage in the renal mitochondria [54, 55] .
In summary, this manuscript describes the developmental urinary metabolomic profiles of preterm neonates, with or without AKI. Using metabolomics, the profiles of AKI and no-AKI neonatal cohorts are differentiated by metabolites related to aminoacyl-t-RNA biosynthesis. Additionally, the pH values of the samples were significantly different, suggesting the influence of the cholinergic receptors in the ICCs in regulating the acid-base balance in the disease state. Gestational age in the no-AKI profiles was best described by metabolites in the aminoacyl-t-RNA biosynthesis pathway, whereas the AKI subjects were better represented by changes in pyruvate metabolism.
A limitation of this exploratory study is that the sample size was small and did not include a validation sample; however, this study found a set of urinary metabolites that clearly differentiated between neonates with and without AKI. The broad spectrum metabolomics and pH results warrant a future targeted metabolomics study in a larger cohort. Validation of the markers identified in this study may assist clinicians with a better diagnosis and treatment of AKI in an at-risk population.
